Health Surveillance at Constructor University Bremen (CUB) 2025
Launched by JACOBS UNIVERSITY BREMEN GGMBH · Mar 21, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Health Surveillance at Constructor University Bremen (CUB) 2025 trial is an observational study focused on understanding the health and well-being of students at Constructor University. The researchers want to find out how factors like social isolation, anxiety, and health behaviors affect students' health. By gathering this information, they hope to identify ways to support students better and improve their overall well-being.
To participate in this study, you need to be a student at Constructor University and be able to read and write in English. It's important that you have internet access since the study will involve online questionnaires and interviews. If you decide to join, you'll help researchers learn more about the challenges students face related to loneliness and anxiety, and your input could lead to better support for future students. If you have serious difficulties with reading or understanding language, you may not be eligible. The study is currently recruiting participants of all genders aged 18 and older.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • English language skills
- • Reading and writing skills
- • Internet access
- • Student status
- • Consent to participate in the study
- Exclusion Criteria:
- • Illiteracy
- • Massively limited cognitive abilities i.e. linguistic components of the digital offerings must be able to be used, and questionnaires completed, or interviews participated in)
About Jacobs University Bremen Ggmbh
Jacobs University Bremen gGmbH is a distinguished private university located in Bremen, Germany, renowned for its interdisciplinary research and innovative educational programs. With a strong emphasis on international collaboration and cutting-edge scientific inquiry, the university actively engages in clinical trials that advance medical research and contribute to the development of novel therapeutic strategies. Its commitment to excellence is reflected in its robust infrastructure, diverse academic community, and partnerships with leading institutions, enabling comprehensive support for clinical research initiatives that aim to improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bremen, , Germany
Bremen, , Germany
Patients applied
Trial Officials
Sonia Lippke, PhD
Principal Investigator
Constructor University Bremen gGmbH & Bremen International Graduate School of Social Sciences, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported